Zerlasiran, a Small-Interfering RNA That Targets Lipoprotein(a)

Elevated lipoprotein(a) levels increase the risk of atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis. Cleveland Clinic’s Steven E. Nissen, MD, speaks with JAMA Executive Editor Gregory Curfman, MD, about how zerlasiran produced more than 80% reductions in time-averaged lipoprotein(a) concentration. Related Content: Zerlasiran—A Small-Interfering RNA Targeting Lipoprotein(a)

Om Podcasten

Interviews with leading researchers and thinkers in health care about practice-changing research, innovations, and the most pressing issues facing medicine and health care today from JAMA, the Journal of the American Medical Association.